Ewan Johnson, MD
Internal Medicine · Tomball, TXNPI 1043521313
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 37 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by AstraZeneca at 26.2% of the total. Reporting peaked in 2019 at $749 and has fallen 98.0% since, to $15 in 2025.
Across 37 payments — averaging $25.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$250
- Amarin Pharma, Inc.$140
- Teva Pharmaceuticals USA, Inc.$111
- AbbVie$75
- Amgen$59
- Sunovion Pharmaceuticals Inc.$59
- plus $260 from 12 others
What the payments were for
- Food & beverage$94999%
- Education$61%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 5 | $250 |
| Amarin Pharma, Inc. | 2 | $140 |
| Teva Pharmaceuticals USA, Inc. | 1 | $111 |
| AbbVie(2 entities) | 4 | $75 |
| Amgen | 3 | $59 |
| Sunovion Pharmaceuticals Inc. | 5 | $59 |
| Currax Pharmaceuticals LLC | 4 | $50 |
| Astellas Pharma US Inc | 2 | $35 |
| Lilly USA, LLC | 2 | $26 |
| Kyowa Kirin, Inc. | 1 | $20 |
| Philips North America LLC | 1 | $17 |
| Nalpropion Pharmaceuticals LLC | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| Novo Nordisk | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$955 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cefdinir | 22 | $256 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 25 | $229 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 16 | $205 |
| Dexamethasone | 16 | $86 |
| Metronidazole | 11 | $70 |
| Meloxicam | 21 | $30 |
| Tramadol Hcl | 15 | $25 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Tomball
- Spencer BerthelsenSugar Land$891K
- Hameed AliTemple$773K
- Marc TribbleDallas$693K
- Gary SinclairDallas$599K
- Mohammed Al-NajjarEl Paso$586K
- Han SchmidlyDallas$465K
- Hussein TawbiHouston$365K
- Hans LeeHouston$327K
- Tapan KadiaHouston$311K
- Nitin JainHouston$281K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.